FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta−Analysis and Bioinformatics Analysis

Zhang, Guangming; Wang, Yongfeng; Han, Xiaoyong; Lu, Tingting; Fu, Liangyin; Jin, Haojie; Yang, Kehu; Cai, Hui

doi:10.3389/fonc.2022.799265

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have demonstrated that lncRNAs are implicated in tumorigenesis and development and are closely related to the prognosis of patients with tumors (Ge et al, 2018;Hu et al, 2021). In previous meta-analyses, FOXP4-AS1 (Zhang et al, 2022b), SNHG15 and SNHG17 (Zhang et al, 2022a) were all linked to the clinicopathological characteristics and prognosis of various malignancies. These findings suggested that lncRNA could be a distinct cancer prognostic biomarker and therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

Zhang

et al. 2022

Front. Genet.

Self Cite

View full text Add to dashboard Cite

Background: Numerous studies have revealed that the long non-coding RNA LINC00662 is irregularly expressed in various cancers, as well as is correlated with cancer development and progression. Nevertheless, the clinical value of LINC00662 remains controversial. Hence, we explored the correlation of LINC00662 with cancer prognosis through meta-analysis and bioinformatics analysis.Methods: From the beginning through 12 March 2022, we searched for correlational studies on Web of Science, Embase, PubMed and The Cochrane Library. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the significance of studies on survival outcomes and clinicopathological aspects in human cancers. Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) database was employed to confirm our findings.Results: Our meta-analysis of 14 studies comprising a total of 960 cancer patients revealed that LINC00662 overexpression was correlated with poor overall survival (HR = 1.91, 95% CI 1.49–2.45, p < 0.001) in cancer patients and relapse-free survival (HR = 2.12, 95% CI 1.19–3.76, p = 0.010) in hepatocellular carcinoma patients. The correlation between LINC00662 and OS was further supported by the results of subgroup analyses according to cancer type, follow-up time, HR availability, and NOS score. In addition, LINC00662 overexpression predicted advanced tumor stage (OR = 4.23, 95% CI 2.50–7.17, p < 0.001), larger tumor size (OR = 1.49, 95% CI 1.11–1.99, p = 0.008), earlier lymph node metastasis (OR = 2.40, 95% CI 1.25–4.59, p = 0.008), and earlier distant metastasis (OR = 4.78, 95% CI 2.57–8.88, p < 0.001). However, there were no statistically significant differences in age (OR = 1.16, 95% CI 0.90–1.51, p = 0.246), gender (OR = 1.10, 95% CI 0.79–1.53, p = 0.578), or differentiation grade (OR = 1.53, 95% CI 0.71–3.33, p = 0.280).Conclusion: LINC00662 expression upregulation is associated with poor prognosis and advanced clinicopathological features in patients with multiple tumors. LINC00662 may serve as a biomarker for the diagnosis and treatment of patients with tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

Zhang

et al. 2022

Front. Genet.

Self Cite

View full text Add to dashboard Cite

show abstract

“…As another research hotspot, 23 studies about SC were included in this study (25,27,36,(44)(45)(46)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(68). Two studies related to circRNA (36,53).…”

Section: Stomach Cancermentioning

confidence: 99%

Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies

et al. 2023

View full text Add to dashboard Cite

AimProvide an overview and a systematic evaluation of the evidence quality on the association between non-coding RNAs (ncRNAs) and prognosis value for gastrointestinal cancers (GICs).MethodsWe searched the literature from three electronic databases: Pubmed, Embase, and Web of science, then carefully screened and extracted the primary information and results from the included articles. We use A measurable systematic review and meta-analysis evaluation tool (AMSTAR2) to evaluate the quality of methodology and then use the Grading of Recommendations Assessment 2, Development and Evaluation guideline (GRADE) make sure the reliability of the meta-analysis.ResultsOverall, 182 meta-analyses from 58 studies were included in this study. Most of these studies are of low or very low quality. Using the scoring tool, we found that only two meta-analyses were rated as high reliability, and 17 meta-analyses were rated as medium reliability.ConclusionsAlthough ncRNA has good prognostic value in some studies, only a tiny amount of evidence is highly credible at present. More research is needed in the future.PROSPERO registration numberCRD42022382296.

show abstract

“…The elevated expression of RP11-357H14.17 and FOXP4-AS1 in GC is linked to reduced overall survival and an unfavorable prognosis. RP11-357H14.17 regulation is also linked with clinical characteristics such as tumor size, differentiation, and metastasis [ 146 , 147 ]. The decreased expression of LINC01939 demonstrated a relation with metastasis and poor prognosis and overall survival in GC [ 148 ].…”

Section: Introductionmentioning

confidence: 99%

Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers

Zabeti Touchaei,

Vahidi,

Samadani

2024

Clin Exp Med

View full text Add to dashboard Cite

Colorectal cancer (CRC) and gastric cancer (GC) are major contributors to cancer-related mortality worldwide. Despite advancements in understanding molecular mechanisms and improved drug treatments, the overall survival rate for patients remains unsatisfactory. Metastasis and drug resistance are major challenges contributing to the high mortality rate in both CRC and GC. Recent research has shed light on the role of long noncoding RNAs (lncRNAs) in the development and progression of these cancers. LncRNAs regulate gene expression through various mechanisms, including epigenetic modifications and interactions with microRNAs (miRNAs) and proteins. They can serve as miRNA precursors or pseudogenes, modulating gene expression at transcriptional and post-transcriptional levels. Additionally, circulating lncRNAs have emerged as non-invasive biomarkers for the diagnosis, prognosis, and prediction of drug therapy response in CRC and GC. This review explores the intricate relationship between lncRNAs and CRC/GC, encompassing their roles in cancer development, progression, and chemoresistance. Furthermore, it discusses the potential of lncRNAs as therapeutic targets in these malignancies. The interplay between lncRNAs, miRNAs, and tumor microenvironment is also highlighted, emphasizing their impact on the complexity of cancer biology. Understanding the regulatory landscape and molecular mechanisms governed by lncRNAs in CRC and GC is crucial for the development of effective diagnostic and prognostic biomarkers, as well as novel therapeutic strategies. This review provides a comprehensive overview of the current knowledge and paves the way for further exploration of lncRNAs as key players in the management of CRC and GC. Graphical Abstract

show abstract

FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta−Analysis and Bioinformatics Analysis

Cited by 5 publications

References 40 publications

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies

Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers

Contact Info

Product

Resources

About